newsfilter
← Earnings
Earnings Releases·

Dianthus Therapeutics — Q3 2026 Earnings Summary

  • Net loss narrowed to $46.6 million ($0.81/share) in Q3 2026 from $36.8 million ($0.97/share) in Q3 2025, driven by a 40% increase in R&D expenses to $45.6 million and a 72% rise in G&A to $14.1 million, while license revenue grew to $1.21 million.
  • The company maintains a robust balance sheet with $1.2 billion in cash, cash equivalents, and investments as of September 30, 2026, providing a projected runway into 2030.
  • Clinical progress includes interim data from the Phase 3 CAPTIVATE trial in CIDP showing a 75% response rate (exceeding the 50% target) and the Phase 2 MoMeNtum trial in MMN exceeding enrollment targets with 46 patients; top-line results for EMERGE (gMG) are expected in H2 2028.
  • Future outlook outlines Phase 2 MoMeNtum top-line data for December 2026, Phase 1 DNTH212 data in Q1 2027, and initiation of a Phase 3 MMN trial in 2027 contingent on MMN results, alongside plans to initiate a Phase 1 MAD study for DNTH212 in Q2 2027.
  • No M&A activity, capital returns, or changes to financial guidance were reported; the company received Orphan Drug Designation for claseprubart in May 2026 and was recognized on the 2026 Fortune Best Workplaces in BioPharma™ list.
Company
DIANTHUS THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology